Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184309 | 1.00 | CYP2C19 (0.52) | CYP2C19GRM1CYP2D6CYP3A4LIMK2 | |
| SCHEMBL3178719 | 0.86 | CYP2C19 (0.43) | CYP2C19GRM1CYP2D6CYP3A4LIMK2 | |
| SCHEMBL3169124 | 0.86 | CYP2C19 (0.43) | CYP2C19GRM1CYP2D6CYP3A4LIMK2 | |
| SCHEMBL7980393 | 0.85 | MAP4K4 (0.48) | CYP2C19GRM1CYP2D6CYP3A4SLC6A7 | |
| SCHEMBL3185289 | 0.76 | PRKCQ (0.42) | CYP2C19 | |
| SCHEMBL16236002 | 0.75 | GRM1 (0.64) | CYP2C19GRM1CYP2D6CYP3A4SLC6A7 | |
| SCHEMBL3628431 | 0.73 | FLT3 (0.47) | — | |
| SCHEMBL3227404 | 0.73 | ROCK1 (0.43) | CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL12100509 | 0.73 | GRM1 (0.70) | GRM1CYP3A4SLC6A7SMOCYP2C9 | |
| SCHEMBL4258836 | 0.72 | TRPV1 (0.55) | GRM1SLC6A7SMOAVPR1ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100016297-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016297-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR3A | CYP2C19 319/4885GRM1 121/4885CYP2D6 84/4885 |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | CYP2C19 411/4885GRM1 105/4885CYP2D6 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.